According to the latest market research study released by Technavio, the global hemophilia drugs market is expected to grow at a CAGR of more than 5% during the forecast period 2016-2020.
This market research report by Technavio provides an in-depth analysis of the market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Click here to request a free sample of this report
Technavio research analysts categorize the global hemophilia drugs market based on type of disease:
Global hemophilia drugs market share by type of disease 2015
|
Hemophilia A |
60.00% |
|
Inhibitors |
20.00% |
|
Hemophilia B |
16.02% |
|
Von Willebrand disease |
3.98% |
Source: Technavio
The top three revenue contributing type of disease segments are discussed below:
Global hemophilia A drugs market
Hemophilia A accounted for around 60% of the global hemophilia drugs market and is expected to grow at a moderate pace during the forecast period. This market is driven by the development of new drugs with protracted action and the increased adoption of prophylactic treatment among individuals. Hemophilia A is more prevalent than hemophilia B and von Willebrand disease and is caused due to the deficiency of clotting factor VIII. The other name of hemophilia A is classical hemophilia or factor VIII deficiency hemophilia. The two main types of hemophilia A are acquired hemophilia A and congenital hemophilia A.
“People with hemophilia A suffer from excessive loss of blood during any injury or trauma, which leads to exhaustion or can also be deadly. Individuals with hemophilia A are cured with recombinant clotting factors or plasma-derived clotting factors, which stops the excessive bleeding. The administration is either prophylactic or therapeutic. Based on the severity, hemophilia A is classified as mild, moderate, and severe,” says Amber Chourasia, a senior analyst at Technavio for research on infections and rare diseases.
Global hemophilia inhibitors treatment market
In 2015, the Inhibitors market accounted for around 20% of the global hemophilia drugs market. These are antibodies that are developed in hemophilia A and B patients against factor VIII or factor IX. Owing to the presence of hemophilia, which also exhibits the same symptoms as uncontrolled bleeding, it is difficult to detect the presence of inhibitors in the body. The presence of inhibitor is confirmed using the Bethesda inhibitor assay. The treatment for inhibitors include high-dose clotting factor concentrates, bypassing agents, and immune tolerance induction (ITI) therapy. They get developed in the body following the treatment for hemophilia A or B. These inhibitors attach themselves to factor VIII or IX and prevent bleeding They destroy the factor concentrates, which were infused for the treatment of hemophilia along with the destruction of factor protein that was naturally produced by the body. It has strong presence in the market of developing countries such as Russia and Iran.
Global hemophilia B drugs market
Hemophilia B accounted for around 16% of the global hemophilia drugs market in 2015 and is expected to grow moderately during the forecast period. However, the market may grow at a fast rate due to the entry of new players. Hemophilia B is a rare X-linked recessive disorder caused by the deficiency of the blood coagulation factor IX. The popular treatment option for hemophilia B is factor replacement therapy. It is also known as factor IX hemophilia or Christmas disease. It is an inherited disorder and about 1/3 of cases occur due to a spontaneous gene mutation. Hemophilia B is present on the X chromosome and males are susceptible to this disease as they have only one X chromosome, while females have two X chromosomes. The gene responsible for the mutated genes need to be present in both the X chromosomes for females to inherit the disease. Females with only a single mutated gene are known as carriers. The available drugs for hemophilia B are expensive, limiting their adoption particularly among developing countries. The acceptance rate of these drugs is comparatively high in the Americas and EMEA than APAC.
The top leading vendors operating in the global hemophilia drugs market are:
- Baxalta
- Bayer
- CSL Behring
- Novo Nordisk
- Pfizer
Other prominent vendors in the market include Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, and UniQure Biopharma.
A more detailed analysis is available in the Technavio report titled, ‘Global Hemophilia Drugs Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Hemophilia B Market 2015-2019 – Industry Analysis
- Global Hemophilia A Drugs Market 2015-2019
- Global Alpha-1 Antitrypsin Drugs Market 2016-2020
- Global Blood Coagulation Analyzer Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
